Form 4: Tyra Biosciences Director Acquires Stock Options

Tyra Biosciences Director Susan Moran acquired stock options under the company's Non-Employee Director Compensation Program.

Summary

• Susan Moran, a Director at Tyra Biosciences, Inc., was granted stock options on May 28, 2026.
• The options grant the right to buy 13,160 shares of common stock at an exercise price of $32.68 per share.
• These options vest monthly over a period of 12 months following the grant date, with full vesting by May 27, 2036.
• Vesting may accelerate to the date of the next annual stockholder meeting if it occurs before the first anniversary of the grant date, provided continuous service is maintained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director, which is a routine event and does not inherently signal positive or negative performance.

Positives

• Director's acquisition of stock options aligns their interests with shareholders.
• The grant is part of a structured Non-Employee Director Compensation Program, indicating established governance practices.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The filing does not contain any negative information.

Risks

• The value of the stock options is subject to market fluctuations and the company's future performance.
• The vesting schedule is contingent on continuous service, meaning unvested options could be forfeited if service is terminated.

Future Outlook

The future outlook is not explicitly detailed in this Form 4 filing, which primarily reports a transaction.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation and reflecting standard compensation structures for non-employee directors in publicly traded companies.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Susan Moran is a related party transaction, as she is a member of the Board of Directors.

Stakeholder Impact

• Shareholders: The alignment of director interests through stock options can be viewed positively, as it incentivizes performance that could lead to share price appreciation. However, dilution from option exercises is a potential consideration.
• Employees: This filing does not directly impact employees.
• Management: The filing confirms standard compensation practices for directors.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The director will continue to provide service to the Issuer through each vesting date.
• The options will vest monthly over 12 months, with potential acceleration to the next annual stockholder meeting date.

Key Dates

Keywords

Tyra Biosciences, TYRA, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Susan Moran